Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Practical Multidisciplinary Approach to Challenging Scenarios from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

Lung Cancer

Combined Impact of Coronary Artery Calcification and Heart Radiation Dose on Overall Survival in Locally Advanced Non-Small Cell Lung Cancer: Who Benefits Most from Reducing Heart Radiation Dose?

Clin Lung Cancer

Watanabe Y, Koide Y, Shimizu H, Aoyama T, Shindo Y, Hashimoto S, Tachibana H, Kodaira T

doi: 10.1016/j.cllc.2025.05.002

Lung Cancer

Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)

J Clin Med

Ruznic E, Klebermass M, Zellinger B, Langer B, Grambozov B, Purevdorj A, Karner J, Gruber G, Stana M, Minasch D, Kirchhammer K, Steffal C, Stranzl H, Moosbrugger R, Feurstein P, Dieckmann K, Zehentmayr F, ALLSTAR Group

doi: 10.3390/jcm14030945

Lung Cancer

A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)

Clin Lung Cancer

Lin JX, Zhou Q, Yan HH, Liu AW, Wu GW, Chu Q, Du YY, Cui JW, Cheng Y, Yang Y, Xu HP, Tu HY, Wu YL, Liu SM

doi: 10.1016/j.cllc.2025.05.014

Lung Cancer

Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study

Lancet Respir Med

Shi Y, Guo Y, Li X, Wu L, Chen Z, Yang S, Bi M, Zhao Y, Yao W, Yu H, Wang K, Zhao W, Sun M, Zhang L, He Z, Lin Y, Shi J, Zhu B, Wang L, Pan Y, Shi H, Sun S, Wen M, Zhou R, Guo S, Han Z, Yi T, Zhang H, Cang S, Yu Z, Zhong D, Cui J, Fang J, Gao J, Li M, Ma R, Jiang M, Qin J, Shu Y, Ye F, Hu S, Li W, Lu H, Yang M, Yi S, Zhang Y, Fan Y, Ji H, Liu Z, Wang H, Zhou X, Zhang D, Peng J, Shen H, Gao F, Wang T, Zhou A

doi: 10.1016/S2213-2600(24)00417-X

Lung Cancer

Cost-effectiveness of hypofractionated radiation therapy versus conventional radiation therapy for unresectable stage III non-small cell lung cancer

Sci Rep

Zhang H, Liu Y, Zeng G, Hu S, Li H, Wang H

doi: 10.1038/s41598-025-28781-1

Lung Cancer

First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial

Lancet Respir Med

Wang L, Hao X, Hao Y, Hu Y, Chen C, Chen B, Huang Y, Zang A, Wang Y, Chen Z, Zhuang W, Shi J, Ren X, Nie L, Yu G, Luo F, Mao Y, Wang X, Li B, Bai Y, Shi J, Ni H, Yu H, Li J, Wang Q, Zhu J, Shi Y, ASTRUM-002 Study Group

doi: 10.1016/S2213-2600(25)00263-2

RECOMMENDED

Lung Cancer

Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Avancini A, Giaj-Levra N, Minuti G, Pasqualini G, Colonese F, Federico AD, Fozza A, Montrone M, Olmetto E, Pastorello E, Reale ML, Riva ST, Roca E, Sini C, Viscardi G, Passiglia F, Pilotto S

doi: 10.1016/j.lungcan.2025.108531

Lung Cancer

Induction Immunochemotherapy Followed by Hypo-Fractionated Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer

Clin Lung Cancer

Zhu Z, Wu J, Zhao L, Jiang N, Chen Y, Song X, Li M, Jiang M, Shi M, Yu S, Ren B, Yin R, Jiang F, Wang L, Kong C, Zhu X

doi: 10.1016/j.cllc.2025.01.012

Lung Cancer

Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter Study

Clin Lung Cancer

Koster KL, Yohasenan S, Pakmak AS, Mark M, Metaxas Y, Lips C, Hitz F, Leskow P, Ludwig C, Putora PM, Glatzer M, Schneider T, Caviezel C, Mader T, Mousavi M, Blum M, Früh M, Joerger M

doi: 10.1016/j.cllc.2025.05.010

Related content

Combined Impact of Coronary Artery Calcification and Heart Radiation Dose on Overall Survival in Locally Advanced Non-Small Cell Lung Cancer: Who Benefits Most from Reducing Heart Radiation Dose?

Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)

A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)

Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study

Cost-effectiveness of hypofractionated radiation therapy versus conventional radiation therapy for unresectable stage III non-small cell lung cancer

First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial

Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study

Induction Immunochemotherapy Followed by Hypo-Fractionated Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer

Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter Study